KLAC vs PLX · P/E 55, rev $13.58B vs P/E 31, rev $53.6M
KLA Corporation (KLAC) versus Protalix Biotherapeutics Inc (PLX) — a side-by-side from cached financials, not a winner call.
KLA Corporation (KLAC) is a semiconductor equipment & materials company listed on US.
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on US.
Latest reported KLAC revenue for 2026-06-30 was $13.58B. Net income was $4.83B. Revenue was up 11.7% from 2025-06-30 to 2026-06-30. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
Latest reported PLX revenue for 2026-06-30 was $53.6M. Net income was $22.1M. Revenue was up 59.0% from 2026-03-31 to 2026-06-30. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
KLAC currently screens at market cap $252.01B and trailing P/E 54.7. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
Not investment advice. Open the KLAC and PLX stock pages for the full models.
Not investment advice.